Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) CFO Molly Henderson Sells 6,583 Shares of Stock

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) CFO Molly Henderson sold 6,583 shares of the company’s stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $6.59, for a total transaction of $43,381.97. Following the completion of the sale, the chief financial officer now directly owns 93,546 shares of the company’s stock, valued at $616,468.14. The trade was a 6.57 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link.

Molly Henderson also recently made the following trade(s):

• On Thursday, December 19th, Molly Henderson sold 1,291 shares of Phathom Pharmaceuticals stock. The shares were sold at an average price of $8.00, for a total transaction of $10,328.00.

Phathom Pharmaceuticals Stock Up 2.6 %

PHAT opened at $7.17 on Friday. Phathom Pharmaceuticals, Inc. has a 12 month low of $6.07 and a 12 month high of $19.71. The firm’s fifty day simple moving average is $8.08 and its 200 day simple moving average is $12.53.

Phathom Pharmaceuticals (NASDAQ:PHAT) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($1.32) EPS for the quarter, beating analysts’ consensus estimates of ($1.57) by $0.25. The firm had revenue of $16.35 million during the quarter, compared to the consensus estimate of $12.54 million. During the same quarter last year, the firm earned ($0.76) earnings per share. On average, research analysts predict that Phathom Pharmaceuticals, Inc. will post -4.74 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the company. HC Wainwright reiterated a “buy” rating and set a $28.00 target price on shares of Phathom Pharmaceuticals in a report on Thursday, December 12th. Needham & Company LLC reiterated a “buy” rating and set a $28.00 price objective on shares of Phathom Pharmaceuticals in a report on Friday, January 10th.

Institutional Investors Weigh In On Phathom Pharmaceuticals

Several institutional investors have recently bought and sold shares of PHAT. Kera Capital Partners Inc. acquired a new stake in shares of Phathom Pharmaceuticals in the fourth quarter valued at approximately $218,000. Barclays PLC increased its stake in Phathom Pharmaceuticals by 366.0% in the 3rd quarter. Barclays PLC now owns 57,807 shares of the company’s stock valued at $1,044,000 after buying an additional 45,402 shares during the last quarter. Geode Capital Management LLC lifted its position in Phathom Pharmaceuticals by 7.1% during the 3rd quarter. Geode Capital Management LLC now owns 862,918 shares of the company’s stock worth $15,605,000 after buying an additional 56,871 shares in the last quarter. MML Investors Services LLC boosted its stake in shares of Phathom Pharmaceuticals by 72.8% during the 3rd quarter. MML Investors Services LLC now owns 33,860 shares of the company’s stock worth $612,000 after buying an additional 14,260 shares during the last quarter. Finally, State Street Corp grew its holdings in shares of Phathom Pharmaceuticals by 17.5% in the 3rd quarter. State Street Corp now owns 922,788 shares of the company’s stock valued at $16,684,000 after acquiring an additional 137,539 shares in the last quarter. Institutional investors own 99.01% of the company’s stock.

Phathom Pharmaceuticals Company Profile

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.